dc.contributor.authorTran, The-Thien
dc.contributor.authorNguyen, Minh-Hiep
dc.contributor.authorTan, Yong Zen
dc.contributor.authorChew, Jia Wei
dc.contributor.authorKhan, Saif A.
dc.contributor.authorHadinoto, Kunn
dc.date.accessioned2016-12-22T07:41:51Z
dc.date.available2016-12-22T07:41:51Z
dc.date.issued2017
dc.identifier.citationTran, T. -T., Nguyen, M. -H., Tan, Y. Z., Chew, J. W., Khan, S. A., & Hadinoto, K. (2016). Millifluidic synthesis of amorphous drug-polysaccharide nanoparticle complex with tunable size intended for supersaturating drug delivery applications. European Journal of Pharmaceutics and Biopharmaceutics, 112, 196-203.en_US
dc.identifier.issn0939-6411en_US
dc.identifier.urihttp://hdl.handle.net/10220/41931
dc.description.abstractThe conventional bulk mixing method to prepare amorphous drug-polysaccharide nanoparticle complex (or drug nanoplex in short) has a major drawback in the lack of size control for the nanoplex produced, hence limiting its potential applications as a supersaturating drug delivery system for bioavailability enhancement of poorly soluble drugs. For this reason, we developed a continuous millifluidic synthesis platform of the drug nanoplex exhibiting high size tunability using curcumin (CUR) and chitosan (CHI) as the models for drug and polysaccharides, respectively. The nanoplex size tunability was achieved by controlling the residence time of the CUR and CHI solutions in the millifluidic reactor, where their slow diffusive mixing at the liquid-liquid interface resulted in a well-regulated nanoplex growth as a function of the residence time. The effects of the preparation pH, molecular weight of CHI, millifluidic tube diameter, and flowrate on the nanoplex size tunability were investigated from which the optimal preparation condition was determined. At the optimal condition, the CUR nanoplex was roughly ≈115 nm in size with zeta potential of ≈15 mV and ≈72% (w/w) CUR payload. The millifluidic synthesis also maintained the high CUR utilization rate (≈80%) exhibited by the bulk mixing method. Most importantly, the ability to produce significantly smaller nanoplex (sixfold smaller) via millifluidics led to the generation of higher (≈8.5× of CUR saturation solubility) and prolonged (≈8 h) supersaturation level. These results bode well for the bioavailability enhancement potential of the drug nanoplex.en_US
dc.format.extent20 p.en_US
dc.language.isoenen_US
dc.relation.ispartofseriesEuropean Journal of Pharmaceutics and Biopharmaceuticsen_US
dc.rights© 2016 Elsevier B. V. This is the author created version of a work that has been peer reviewed and accepted for publication by European Journal of Pharmaceutics and Biopharmaceutics, Elsevier. It incorporates referee’s comments but changes resulting from the publishing process, such as copyediting, structural formatting, may not be reflected in this document. The published version is available at: [http://dx.doi.org/10.1016/j.ejpb.2016.11.030].en_US
dc.subjectMillifluidicsen_US
dc.subjectMicrofluidicsen_US
dc.titleMillifluidic synthesis of amorphous drug-polysaccharide nanoparticle complex with tunable size intended for supersaturating drug delivery applicationsen_US
dc.typeJournal Article
dc.contributor.schoolSchool of Chemical and Biomedical Engineeringen_US
dc.identifier.doihttp://dx.doi.org/10.1016/j.ejpb.2016.11.030
dc.description.versionAccepted versionen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record